All microbicide effectiveness studies are currently designed with HIV infection as the primary ... reformulated tenofovir gel and 2% N-9 Replication inhibitor/surfactant [109] †Note the ...
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.
has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved Pifeltro (doravirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), as well as Delstrigo ...
Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat ...
By doing so, HIV can begin to churn out multiple copies of itself. Nucleoside reverse transcriptase inhibitors (NRTIs) block the action of reverse transcriptase and so prevent the replication of the ...
Warfarin was associated with more risk than apixaban (Eliquis; 55.38 vs 21.42 per 1,000 person-years, HR 2.60, 95% CI ...
Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...